This article is more than 5 years old. Information may no longer be current.
Upcoming ASPC Congress highlights genetics, women’s health and more
Click Here to Manage Email Alerts
The American Society for Preventive Cardiology 2018 Congress on CVD Prevention, running from July 27 to 29, will provide attendees with a look at new advancements in CVD prevention, management and treatment.
The 3-day event will take place at the Hyatt Regency Tamaya Resort in Santa Ana Pueblo, New Mexico.
Sekar Kathiresan, MD, a world-renowned physician scientist and human geneticist, will be the keynote speaker on Friday, July 27. Kathiresan, who is associate professor of medicine at Harvard Medical School, will address CVD prevention in genetics. His talk will focus on how the discovery of mutations associated with CVD opens the possibility of novel therapies to help people decrease the risk for future events.
On Saturday, July 28, Lori Mosca, MD, MPH, PhD, director of Preventive Cardiology at New York-Presbyterian Hospital, will present the Nanette K. Wenger Distinguished Lecture. Mosca, past president of the American Society for Preventive Cardiology (ASPC), is an internationally recognized expert on preventive cardiology and women’s health. She will discuss the American Heart Association’s Go Red for Women national movement and its impact on prevention of CVD and stroke in women.
The closing presentation on Sunday, July 29, will feature a debate on the usefulness of measuring lipoprotein(a) in patients with high CVD risk. Patrick Moriarty, MD, professor of internal medicine at University of Kansas, will argue the pro side, highlighting the need to measure Lp(a) in patients with high CVD risk factors. Sergio Fazio, MD, PhD, chair of preventive cardiology, professor of medicine and physiology and pharmacology at Oregon Health and Science University, will present a different viewpoint, arguing why there is a need to measure Lp(a). Relevant to this discussion, Lp(a) was recently given a unique ICD-10 code, E78.8.
The ASPC Congress will also feature a Town Hall forum, titled “Gaining Access to PCSK9 Inhibitors: Using the ASPC Novel App.” In the Town Hall, speakers will review the history of issues relating to, and recommendations for, improving the process to access PCSK9 inhibitors for patients, clinicians, and payers. The discussion will provide a step-by-step tutorial on how to use the novel app to more efficiently access PSCK9 inhibitors.
Attendees will have the opportunity to connect with the faculty and other prominent preventive cardiology leaders. During the conference, practitioners will gain real-world perspective on how to translate current CVD prevention research into effective treatment strategies for clinical practice.
Cardiology Today and Healio.com/Cardiology will provide live coverage from the ASPC Congress, including reports on the sessions, onsite video interviews and much more. For more information before, during and after the meeting, visit this link.